← Back to headlines
Summit Therapeutics Reveals Phase II AK112-206 Trial Data
Summit Therapeutics (SMMT) has disclosed data from its Phase II AK112-206 clinical trial, providing an update on the drug's development and efficacy.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
